Skip to content

Clinical study to evaluate efficacy and safety of Kamishoyosan for Premens trual syndrome

An open-label, randomized clinical study to evaluate efficacy and safety of Kamishoyosan for Premenstrual syndrome

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs061220001
Enrollment
50
Registered
2022-04-11
Start date
2022-04-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premenstrual syndrome

Interventions

Kamishoyosan administration

Sponsors

Taniguchi Fuminori
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with PMS based on ACOG PMS diagnostic criteria 2) Patients who meet a toral score of 30 or higher on premenstrual MDQ at pretreatment period 3) Patients aged 18 to 45 at the time of consent 4) Patients with regular menstrual cycle of 25 to 38 days 5) Patients who can take study drugs orally 6) Outpatient

Exclusion criteria

Exclusion criteria: 1) Patients who have been treated with oral contraceptives or sex hormones within 4 weeks before obtaining consent 2) Patients who have been treated with antidepressants within 4 weeks before obtaining consent 3) Patients who have been treated with anxiolytics within 4 weeks before obtaining consent 4) Patients who have been treated with sleeping pills within 4 weeks before obtaining consent 5) Patients who have been treated with diuretics within 4 weeks before obtaining consent 6) Patients who have been treated with effective drug against PMS within 4 weeks before obtaining consent 7) Patients with serious mental disease 8) Patients with serious disease 9) Patients who are pregnant or may be pregnant and wish to become pregnant 10) Patients who are lactating women 11) Patients with allergies to Kampo medicines 12) Patients who participated in clinical trials or other clinical studies within 3 months before obtaining consent 13) Patients treated with study drug within 4 weeks prior to consent

Design outcomes

Primary

MeasureTime frame
Pre-menstrual MDQ Total score change from baseline to final evaluation

Secondary

MeasureTime frame
1) Change over time of MDQ (Pre-menstrual total score, mid-menstrual total score, post-menstrual total score, each subscale score) 2) Sleep evaluation 3) Evaluation specific to Kampo Medicine 4) Menstruation-related symptom evaluation 5) Work Productivity and Activity Impairment Questionnaire 6) Cold, stiff shoulder score 7) Overall impression after participating in the research 8) Sleep/heart rate evaluation using a smart watch 9) Adversed experience

Contacts

Public ContactYusuke Endo

Tottori University Hospital

y-endo@tottori-u.ac.jp+81-859-38-6946

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026